Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Gains from Investment Securities: 2020-2025

  • Arcutis Biotherapeutics' Gains from Investment Securities rose 754.29% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year change of. This contributed to the annual value of $3.6 million for FY2020, which is 825.06% up from last year.
  • Arcutis Biotherapeutics' Gains from Investment Securities amounted to $3.2 million in Q3 2025, which was up 754.29% from -$490,000 recorded in Q3 2024.
  • Over the past 5 years, Arcutis Biotherapeutics' Gains from Investment Securities peaked at $3.2 million during Q3 2025, and registered a low of -$490,000 during Q3 2024.
  • Moreover, its 2-year median value for Gains from Investment Securities was $1.4 million (2024), whereas its average is $1.4 million.
  • Data for Arcutis Biotherapeutics' Gains from Investment Securities shows a peak YoY spiked of 754.29% (in 2025) over the last 5 years.
  • Over the past 2 years, Arcutis Biotherapeutics' Gains from Investment Securities (Quarterly) stood at -$490,000 in 2024, then spiked by 754.29% to $3.2 million in 2025.
  • Its Gains from Investment Securities was $3.2 million in Q3 2025, compared to -$490,000 in Q3 2024 and -$28,000 in Q4 2020.